Anondita Medicare Ltd
Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.”[1]
- Market Cap ₹ 2,167 Cr.
- Current Price ₹ 1,198
- High / Low ₹ 1,316 / 262
- Stock P/E 64.8
- Book Value ₹ 71.5
- Dividend Yield 0.00 %
- ROCE 43.6 %
- ROE 40.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 16.8 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 77 | 137 | |
| 51 | 87 | |
| Operating Profit | 26 | 51 |
| OPM % | 33% | 37% |
| 0 | 1 | |
| Interest | 3 | 4 |
| Depreciation | 1 | 1 |
| Profit before tax | 22 | 47 |
| Tax % | 25% | 27% |
| 16 | 34 | |
| EPS in Rs | 11.88 | 18.49 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 78% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 112% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 40% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13 | 18 |
| Reserves | 25 | 111 |
| 27 | 34 | |
| 13 | 22 | |
| Total Liabilities | 78 | 185 |
| 14 | 84 | |
| CWIP | 6 | 0 |
| Investments | 3 | 0 |
| 55 | 101 | |
| Total Assets | 78 | 185 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -10 | 11 | |
| -23 | -63 | |
| 33 | 61 | |
| Net Cash Flow | -0 | 9 |
| Free Cash Flow | -30 | -52 |
| CFO/OP | -38% | 28% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 127 | 138 |
| Inventory Days | 141 | 126 |
| Days Payable | 40 | 49 |
| Cash Conversion Cycle | 228 | 215 |
| Working Capital Days | 129 | 163 |
| ROCE % | 44% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Annual Production Volume lakhs pieces |
|
|||
| Capacity Utilization Rate % |
||||
| Installed Production Capacity lakhs pieces |
||||
| Number of Distributors number |
||||
| Number of Retailers number |
||||
| Number of Super Stockists number |
||||
| Total Manufacturing Lines number |
||||
Extracted by Screener AI
Documents
Announcements
-
Giving guarantees/indemnity/ becoming a surety for third party
29 June 2026 - NSE granted in-principle approval for 2,85,000 promoter warrants at Rs1,038 each on June 25, 2026.
-
Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
29 June 2026 - NSE granted in-principle approval for 2,85,000 warrants at ₹1,038 each to promoters.
-
Reply to Clarification- Financial results
25 June 2026 - Reported IPO proceeds utilization for H1 FY26 and September 30, 2025 financial results.
-
Clarification - Financial Results
25 June 2026 - Exchange has sought clarification from Anondita Medicare Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Updates
24 June 2026 - Anondita Medicare submitted audited standalone and consolidated FY26 results with auditors' report on June 24, 2026.
Annual reports
No data available.
Business Profile:[1]
Anondita Medicare manufactures male (and recently, female) condoms, flagship brand “COBRA,” with in-house printing/packaging and 100% electronic testing.